Pieris Pharmaceuticals, Inc.:
Platform technology company developing Anticalin proteins (engineered human lipocalins) for respiratory diseases and oncology. Upcoming Phase 1 data for data for: 1) AZN-partnered PRS-060 for moderate-to-severe asthma (targeting IL4RA through inhalation) and 2) fully-proprietary IO program PRS-343 for HER2+ solid tumors (targeting 4-1BB and HER2). IO partnerships w/ Servier and Seattle Genetics.
Phase l or ll
Immuno-Oncology, Immunotherapy, Oncology, Respiratory
100MM - 500MM
Antibodies, Platform Technology
255 State Street
Boston, MA 02109
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by